Assess whether scientific advice should be sought before the next trial

SITUATION The working file is draft labeling vs. the clinical study report after an inspector asking for batch records you cannot produce this week. 505(b)(2) development lead in a safety team sitting on a new disproportionate signal has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance file.

DECISION 505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using draft labeling vs. the clinical study report after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. 505(b)(2) development lead can defend Proceed under protocol from draft labeling vs. the clinical study report after an inspector asking for batch records you cannot produce this week in a Pharma & Life Sciences challenge. 2. 505(b)(2) development lead cannot defend Proceed under protocol from draft labeling vs. the clinical study report; Pause the pathway is what the extract actually supports after an inspector asking for batch records you cannot produce this week. 3. An inspector asking for batch records you cannot produce this week never reached the population in draft labeling vs. the clinical study report — reopen intake, do not close scientific advice should be. 4. Two facts in draft labeling vs. the clinical study report after an inspector asking for batch records you cannot produce this week conflict for 505(b)(2) development lead; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Check whether draft labeling vs. the clinical study report supports the labeled claim 505(b)(2) development lead would keep. 2. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 3. Trace CMC, labeling, or pharmacovigilance facts in draft labeling vs. the clinical study report after an inspector asking for batch records you cannot produce this week. 4. For this Pharma & Life Sciences Pharmacovigilance file, read draft labeling vs. the clinical study report against an inspector asking for batch records you cannot produce this week and write the one fact that would move scientific advice should be for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (draft labeling vs. the clinical study report after an inspector asking for batch records you cannot produce this week). The follow-on Pharmacovigilance action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.